Corriente Advisors, LLC Cardiff Oncology, Inc. Transaction History

Corriente Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $6.93 Million - $10.5 Million	-1,383,500 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.65 - $10.04 $9.32 Million - $14.1 Million	-1,401,910 Reduced 50.33%	1,383,500 $9.2 Million
Q1 2021 May 18, 2021	BUY	$9.1 - $19.57 $7.15 Million - $15.4 Million	785,410 Added 39.27%	2,785,410 $25.8 Million
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $13.1 Million - $26.9 Million	1,090,000 Added 119.78%	2,000,000 $36 Million
Q3 2020 Nov 03, 2020	BUY	$4.25 - $14.19 $3.13 Million - $10.5 Million	736,639 Added 424.92%	910,000 $12.9 Million
Q2 2020 Aug 14, 2020	BUY	$0.78 - $5.1 $135,221 - $884,141	173,361 New	173,361 $869,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $106M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Corriente Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Corriente Advisors, LLC with notifications on news.